0001354457-22-000652 25-NSE 2 20221116 20221116 20221116 Stealth BioTherapeutics Corp 0001696396 2834 000000000 E9 1231 25-NSE 34 001-38810 221393523 190 ELGIN AVENUE GEORGE TOWN GRAND CAYMAN E9 KY1-9005 617-600-6888 190 ELGIN AVENUE GEORGE TOWN GRAND CAYMAN E9 KY1-9005 Nasdaq Stock Market LLC 0001354457 521165937 DE 1231 25-NSE One Liberty Plaza New York NY 10006 301-978-4144 Office of General Counsel 805 King Farm Blvd. ROCKVILLE MD 20850 The Nasdaq Stock Market LLC 20060224 25-NSE 1 primary_doc.xml UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38810 Issuer: Stealth BioTherapeutics Corp Exchange: Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Address: 140 Kendrick Street, Building C West Needham, MASSACHUSETTS 02494 Telephone number: 617-340-3289 (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices) American Depositary Shares (Description of class of securities) Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration: [ ] 17 CFR 240.12d2-2(a)(1) [ ] 17 CFR 240.12d2-2(a)(2) [x] 17 CFR 240.12d2-2(a)(3) [ ] 17 CFR 240.12d2-2(a)(4) [ ] Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1 [ ] Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange. Pursuant to the requirements for the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person. 2022-11-16 By Tara Petta AVP Date Name Title 1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions. EX-99.25 2 form25.txt Form 25